Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome

Chinese Medical Journal

Volumn 120, Issue 17, 2007, Pages 1482-1486

  Ye, Jin ^a   Liu, Hui ^a   Li, Yuan ^a   Liu, Xian ^a   Zhu, Jie Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

C reactive protein; Cardiovascular diseases; Intermittent hypoxia; Matrix metalloproteinase; Obstructive sleep apnea

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FREQUENCY ANALYSIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYSOMNOGRAPHY; PROTEIN BLOOD LEVEL; SLEEP APNEA SYNDROME; STATISTICAL SIGNIFICANCE; UPREGULATION;

EID: 34848900406     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200709010-00003     Document Type: Article

References (25)

1. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829-1836.
2. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
3. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-1914.
4. Kasasbeh E, Chi DS, Krishnaswamy G. Inflammatory aspects of sleep apnea and their cardiovascular consequences. South Med J 2006; 99: 58-67.
5. Vasan RS. Biomarkers of cardiovascular disease molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.
6. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
7. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139-1147.
8. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different Pathologies. Circulation 2002; 105: 2019-2023.
9. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109: 2850-2856.
10. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211-217.
11. Shamsuzzaman AS, Winnicik M, Lanfranchi P, Wolk R, Kara T, Accurso V, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-2464.
12. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoquchi H, Yoshino G, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-1134.
13. Can M, Açikgoz S, Mungan G, Bavraktaroqlu T, Kocak E, Guven B, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129: 233-237.
14. Tazaki T, Minoguchi K, Yokoe T, Samson KT, Minoguchi H, Tanaka A, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 170: 1354-1359.
15. Tong MR, Tong MQ. Sleep stages standard criteria of adult. In: Tong MR, Pei L, Tong MQ, Susumu S, eds. Textbook of polysomnogramology. Beijing: People's Military Medical Press; 2004: 33-63.
16. Steven MH, Andrew SG, Wayde MW, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
17. Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse T. Involvement of inflammation in acute coronary syndromes assessed by levels of high sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol 2003; 42: 201-206.
18. Chen P, Yuan Y, Wang S, Zhan L, Xu J. Serum matrix metalloproteinase 9 as a marker for the assessment of severe acute pancreatitis. Tohoku J Exp Med 2006; 208: 261-266.
19. Lin R, Liu J, Gan W, Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 2004; 27: 1537-1543.
20. Abe N, Osanai T, Fujiwara T, Kameda K, Mutsunaga T, Okumura K. C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci 2006; 78: 1021-1028.
21. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-1378.
22. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
23. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86: 1259-1265.
24. Suzuki YJ, Jain V, Park AM, Day RM. Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic Biol Med 2006; 40: 1683-1692.
25. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.